Short drug course aims to unmask immune changes in early breast cancer
NCT ID NCT06710197
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 32 times
Summary
This study was designed to see how a 14-day course of an IL-1 blocking drug (Anakinra) changes the immune environment inside early-stage triple-negative or ER-low breast cancer tumors. Researchers planned to compare tumor samples taken before and after treatment in about 0 participants. The study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE TRIPLE NEGATIVE ER LOW BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Health Network-Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.